Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Vycor Medical (VYCO) EBIT Margin (2016 - 2025)

Vycor Medical has reported EBIT Margin over the past 16 years, most recently at 8.76% for Q4 2025.

  • Quarterly EBIT Margin fell 1009.0% to 8.76% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.82% through Dec 2025, up 323.0% year-over-year, with the annual reading at 1.82% for FY2025, 323.0% up from the prior year.
  • EBIT Margin was 8.76% for Q4 2025 at Vycor Medical, down from 6.24% in the prior quarter.
  • Over five years, EBIT Margin peaked at 19.99% in Q2 2023 and troughed at 69.94% in Q1 2021.
  • The 5-year median for EBIT Margin is 8.51% (2023), against an average of 12.74%.
  • Year-over-year, EBIT Margin soared 8639bps in 2021 and then tumbled -2746bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 59.99% in 2021, then soared by 44bps to 33.62% in 2022, then skyrocketed by 38bps to 20.78% in 2023, then skyrocketed by 106bps to 1.32% in 2024, then tumbled by -762bps to 8.76% in 2025.
  • Per Business Quant, the three most recent readings for VYCO's EBIT Margin are 8.76% (Q4 2025), 6.24% (Q3 2025), and 10.3% (Q2 2025).